Holly McConville

University of Pennsylvania — United States

Medicine · Health Sciences

9h-index720citations15works58.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(13), Chronic Lymphocytic Leukemia Research(6), Immunotherapy and Immune Responses(5), Virus-based gene therapy research(2), Multiple Myeloma Research and Treatments(2)

Publications15 total

Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies
Nature Medicine·2025· 58 cited
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
Nature Medicine·2022· 456 citedOpen Access
CAR T-Cell Therapy Effects: Review of Procedures and Patient Education
Clinical journal of oncology nursing·2017· 11 cited
Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL.
Journal of Clinical Oncology·2016· 32 cited
Chimeric antigen receptor modified T cells directed against CD19 (CTL019) induce clinical responses in patients with relapsed or refractory CD19+ lymphomas
Cytotherapy·2015· 2 cited
Phase IIa Trial of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas
Blood·2014· 19 cited
Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL
Blood·2014· 64 cited
SP-024 CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR-MODIFIED T CELLS FOR RELAPSED, REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Leukemia Research·2014
Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL
Blood·2013· 29 cited
Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL
Blood·2013· 20 cited
A phase II, dose-optimization trial of autologous T cells genetically engineered to express anti-CD19 chimeric antigen receptor (CART-19) in patients with relapsed or refractory (r/r) CD19+ chronic lymphocytic leukemia (CLL).
Journal of Clinical Oncology·2013· 6 cited
Adoptive transfer of gene-modified T-cells engineered to express high-affinity tcr's for cancer-testis antigens NY-ESO-1 or lage-1, in multiple myeloma (MM) patients post autologous hematopoietic stem cell transplant (ASCT)
Cytotherapy·2013· 2 cited
Combination Immunotherapy After ASCT for Multiple Myeloma (MM) Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-Cells
Blood·2012· 5 cited
Prolonged T Cell Persistence, Homing to Marrow and Selective Targeting of Antigen Positive Tumor in Multiple Myeloma Patients Following Adoptive Transfer of T Cells Genetically Engineered to Express an Affinity-Enhanced T Cell Receptor Against the Cancer Testis Antigens NY-ESO-1 and Lage-1
Blood·2012· 4 cited
Adoptive Transfer of Gene-Modified T-Cells Engineered to Express High-Affinity TCRs for Cancer-Testis Antigens (CTAs) NY-ESO-1 or Lage-1, in MM Patients Post Auto-SCT
Blood·2012· 12 cited

Frequent Co-authors

Carl H. June(14), Bruce L. Levine(13), Anne Chew(11), Michael Kalos(8), Zhaohui Zheng(8), Joan Gilmore(7), Lester Lledo(7), Norbert Frey(7), Simon F. Lacey(6), Elizabeth Veloso(6), Alison W. Loren(6), Stephan A. Grupp(5), James Capobianchi(5), Edward A. Stadtmauer(5), Wei‐Ting Hwang(4), Irina Kulikovskaya(4), David Porter(4), Katherine T. Marcucci(4), Stephen J. Schuster(4), David L. Porter(4)